Cellectis shares are trading higher after the company announced the FDA granted orphan drug and rare pediatric designation disease to UCART22.
Portfolio Pulse from Benzinga Newsdesk
Cellectis shares are trading higher after the company announced the FDA granted orphan drug and rare pediatric designation disease to UCART22.
July 26, 2024 | 12:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cellectis shares are trading higher following the FDA's grant of orphan drug and rare pediatric designation to UCART22, which is likely to boost investor confidence and potentially lead to increased funding and partnerships.
The FDA's grant of orphan drug and rare pediatric designation to UCART22 is a significant milestone for Cellectis, as it can lead to market exclusivity, tax credits, and potential funding opportunities. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100